Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Condition:   Multiple Myeloma Intervention:   Biological: IM21 CART Sponsors:   Peking Union Medical College Hospital;   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials